Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity

• Published in: PloS one Vol. 14; no. 10; p. e0223555
• Main Authors: Jin, Dan, Tran, Nguyen, Thomas, Nagheme, Tran, David D.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 10.10.2019; Public Library of Science (PLoS)
• Subjects: Aminopyridines - pharmacology; Biology and Life Sciences; Brain cancer; Brain research; Breast; Breast cancer; Cancer; Cancer therapies; Carboplatin; Cell cycle; Cell Cycle Checkpoints - drug effects; Cell Death - drug effects; Cell division; Cell Line, Tumor; Combination drug therapy; Cyclin-dependent kinase 4; Cyclin-Dependent Kinase 4 - antagonists & inhibitors; Cyclin-Dependent Kinase 4 - metabolism; Cyclin-Dependent Kinase 6 - antagonists & inhibitors; Cyclin-Dependent Kinase 6 - metabolism; Cytotoxic agents; Cytotoxicity; Drug Liberation; Drug Therapy, Combination; Drugs; Humans; Inhibitors; Kinases; Lung cancer; Medical research; Medical schools; Medicine; Medicine and Health Sciences; Metastasis; Neurosurgery; Oncology; Palbociclib; Piperazines - pharmacology; Proteins; Purines - pharmacology; Pyridines - pharmacology; Regulatory approval; Ribociclib; S Phase - drug effects; Schedules; Senescence; Solid tumors; Targeted cancer therapy; Toxicity; Tumor cell lines; Tumors; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0223555

Cyclin-dependent kinases 4 and 6 (CDK4/6) play critical roles in the G1 to S checkpoint of the cell cycle and have been shown to be overactive in several human cancers. Small-molecule inhibitors of CDK4/6 have demonstrated significant efficacy against many solid tumors. Since CDK4/6 inhibition is thought to induce cell cycle arrest at the G1/S checkpoint, much interest has been focused on combining CDK4/6 inhibitors with cytotoxic agents active against the S or M phase of the cell cycle to enhance therapeutic efficacy. However, it remains unclear how best to combine these two classes of drugs to avoid their potentially antagonistic effects. Here, we test various combinations of highly selective and potent CDK4/6 inhibitors with commonly used cytotoxic drugs in several cancer cell lines derived from lung, breast and brain cancers, for their cell-killing effects as compared to monotherapy. All combinations, either concurrent or sequential, failed to enhance cell-killing effects. Importantly, in certain schedules, especially pre-treatment with a CDK4/6 inhibitor, combining these drugs resulted in reduced cytotoxicity of cytotoxic agents. These findings urge cautions when combining these two classes of agents in clinical settings.